Fig. 1 · Structure

Documents & Downloads

ARL-15896

Cat. No. A13858 CAS 153322-06-6

NMDA receptor ion channel antagonist

ARL-15896 is a novel N-methyl-D-aspartate receptor ion channel antagonist.

In Stock

Publications for ARL-15896

1 publication citing this product

  1. Robert A. Volkmann, .et al. , PLoS One, 2016, 11(2): e0148129 PMID: 26829109

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

ARL-15896 inhibited glutamate/glycine-evoked calcium responses in HEK cells expressing human NMDA receptors containing GluN2B or GluN2D. These functional results support NMDA receptor antagonism under the reported assay conditions; they do not establish a universal potency or subtype-selective mechanism. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

ARL-15896 Research Summary

This section summarizes 1 in vitro study and 1 in vivo study of ARL-15896 from 2 published references.

ARL-15896 In Vitro Studies

In the HEK calcium assay, reported ARL-15896 IC50 values were 510,000 ± 240,000 nM for GluN2B and 25,000 ± 8,000 nM for GluN2D (mean IC50 ± SEM; three replicate curves each). GluN2A was not determined. The values are assay endpoints, not treatment recommendations. [1]

ARL-15896 inhibition of recombinant NMDA receptor calcium responses

Cell-based study · HEK cells expressing human NMDA receptor subtypes containing GluN2B or GluN2D [1]

The reference-antagonist comparison reports inhibition of agonist-evoked calcium responses. GluN2A was not determined for ARL-15896; the subtype results do not establish universal potency or a selective mechanism.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
GluN2B-containing receptor calcium responseIC50 510,000 ± 240,000 nM (n = 3 replicate curves; mean IC50 ± SEM)[1]
GluN2D-containing receptor calcium responseIC50 25,000 ± 8,000 nM (n = 3 replicate curves; mean IC50 ± SEM)[1]

Literature-Reported Treatment Conditions

Treatment concentration
Concentration-response series; individual ARL-15896 test concentrations not specified in Table 1. Agonists: glutamate and glycine, 3 μM each as reported.
Exposure duration
10 min compound preincubation; 20 s fluorescence baseline and 3 min recording after agonist addition in the shared assay method.
Method
Fluo-8 calcium fluorescence, FDSS 6000; Hill-equation IC50 fitting using CDD Vault.
Co-treatment
Glutamate plus glycine stimulation; comparator antagonists were tested separately.
Reported limits
ARL test concentration series, exact salt/CAS, lot and ARL-specific solvent are not specified in the selected table/shared method. The detailed cell preparation describes GluN2A cells; subtype-specific preparation for B/D is not separately detailed there.
Methods and source locations

Compound reported in the paper: ARL-15896; Compound label in the paper: ARL-15896

Reported ARL-15896 assay evidence only; no salt conversion, stereochemical assay validation or Adooq lot validation.

Table 1 (ARL-15896 row, headings and footnote); Results opening paragraph; Materials and Methods: Reagents, Primary screening assays

GluN2B-containing receptor calcium response: Inhibition of glutamate/glycine-evoked calcium fluorescence; Hill fit. — Table 1, ARL-15896 row; column headings and footnote

GluN2D-containing receptor calcium response: Inhibition of glutamate/glycine-evoked calcium fluorescence; Hill fit. — Table 1, ARL-15896 row; column headings and footnote

ARL-15896 In Vivo Studies

Lanicemine (also named AZD6765 and AR-R 15896AR) increased spontaneous gamma-band EEG in male Sprague-Dawley rats after intraperitoneal administration. Locomotor activation was lower than with ketamine at comparable EEG target engagement. The tested salt form was unspecified, and these endpoints do not establish antidepressant efficacy. [2]

Rat cortical gamma EEG and locomotor response to lanicemine

Animal study · Male Sprague-Dawley rats performing an auditory operant task; n = 6–9 as reported in methods. [2]

Lanicemine increased spontaneous gamma-band EEG in a dose-dependent manner. At comparable EEG target engagement, locomotor activation was lower than with ketamine. These are neurophysiological and behavioral endpoints, not evidence of antidepressant efficacy in rats.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Spontaneous gamma-band EEG and locomotor activityQualitative dose-response comparison Dose-dependent gamma-band EEG elevation; locomotor activity less coupled to EEG target engagement than for ketamine.[2]

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
Single acute administration per assessment
Treatment course
EEG assessed for 1.5 h after dosing
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Lanicemine dose series
3, 10 or 30 mg kg−1
Respective vehicle control; ketamine 1, 3, 10 or 30 mg kg−1 comparator.Increased gamma EEG; lower locomotor activation than ketamine at comparable EEG target engagement. Figure 1 left illustrates 10 mg kg−1 and respective vehicles; right compares dose series.[2]
Lanicemine dose series
Model: Male Sprague-Dawley rats; n = 6–9 stated collectively in methods.
Reported limits: Group-specific n, vehicle composition, exact salt and lot not specified in read rodent methods/caption.
Methods and source locations

Compound reported in the paper: Lanicemine (AZD6765; AR-R 15896AR); Compound label in the paper: Lanicemine

Named lanicemine rodent pharmacology; no salt-specific dose translation or lot validation.

Materials and methods: Effects of ketamine and lanicemine on EEG in rodent models; Results/Discussion rodent EEG paragraph; Figure 1 and caption

Spontaneous gamma-band EEG and locomotor activity: Frontal and temporal skull-screw EEG, Fourier-derived power; normalized post/pre-dose spectral power and locomotor comparison in Figure 1. — Materials and methods: Effects of ketamine and lanicemine on EEG in rodent models; Results/Discussion rodent EEG paragraph; Figure 1 and caption

Lanicemine dose series · Materials and methods: Effects of ketamine and lanicemine on EEG in rodent models; Results/Discussion rodent EEG paragraph; Figure 1 and caption

Specifications

Manufacturer Adooq Bioscience
Actions Antagonist
CAS Number 153322-06-6
Applications NMDA receptor ion channel antagonist
Formula C13H16Cl2N2
Molecular Weight 271.19187
Synonyms Lanicemine hydrochloride; AR-R15896AR
SMILES
C1=CC=C(C=C1)[C@H](CC2=CC=CC=N2)N.Cl.Cl

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

ARL-15896 Research References

  1. [1] Volkmann RA, Fanger CM, Anderson DR, et al. MPX-004 and MPX-007: New Pharmacological Tools to Study the Physiology of NMDA Receptors Containing the GluN2A Subunit. PloS one (2016). PMID: 26829109 DOI: 10.1371/journal.pone.0148129 Source material
  2. [2] Sanacora G, Smith MA, Pathak S, et al. Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects. Molecular psychiatry (2014). PMID: 24126931 DOI: 10.1038/mp.2013.130 Source material

Publications

1 publication citing this product

  1. Robert A. Volkmann, .et al. , PLoS One, 2016, 11(2): e0148129 PMID: 26829109

Added to your cart

View Cart Checkout
Loading...